Scotiabank analyst George Farmer raised the firm’s price target on Argenx to $408 from $402 and keeps a Sector Perform rating on the shares. The firm revised its estimates upward following a review of the company’s 20-F filing and revisit of product revenue, the analyst tells investors. There are several key catalysts heading into 2024, including results from three Phase 2 trials evaluating efgart in Sjogren’s and myositis and post-Covid POTS, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s VYVGART Wins Approval in Japan for ITP
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
- Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
- Immunovant rallies after Chugai myasthenia gravis study failure
- Argenx rallies after Chugai generalized myasthenia gravis study fails
